Galapagos raises $52M for new molecule deals; Novartis: New H7N9 vaccine ready for trials in 6 to 8 weeks;

 @FierceBiotech: Still trending: Merck scores 'breakthrough' status from FDA for immunotherapy against melanoma. Report | Follow @FierceBiotech

 @JohnCFierce: Lotso chatter about tivozanib this morning. Personally, I suspect the FDA will give it an OK, then Aveo will face a kickback in commercial. | Follow @JohnCFierce

 @RyanMFierce: Treato scores $14.5M VC round, tackles social media analytics for pharma. Release | Follow @RyanMFierce

> Galapagos NV plans to raise about $52 million to fund new drug deals as well as pursue later-stage clinical R&D activities. Story

> Novartis ($NVS) CEO Joe Jimenez says the company has begun working on an H7N9 vaccine, adding that new technology will make it possible to whip up a new vaccine for clinical trials in "six to eight weeks." Story

> Retrophin has named Horacio Plotkin as chief medical officer. He'll be based in Cambridge, MA, where Retrophin plans to open an office for its clinical, medical, and regulatory operations. Release

> Daiichi Sankyo has stepped in to support an early-stage study of PER977, an experimental drug from Perosphere designed to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor. Release

Medical Device News

 @FierceMedDev: Missouri Sen. accuses medical equipment companies of wasteful billing. Item | Follow @FierceMedDev

 @MarkHFierce: Today's DxExtra: a look at a UK effort to develop an early pancreatic cancer Dx tool. Article | Follow @MarkHFierce

 @DamianFierce: Mounting recall charges ate away Stryker's modest revenue growth in Q1. Report | Follow @DamianFierce

> CardioDx reaches to India with Core partnership. News

> Cook recalls Zilver PTX over delivery problem. Story

> Boston Scientific loses $354M in Q1. Article

Pharma News

 @FiercePharma: Check out Argentina for pharma market growth: New research forecasts $15b by 2020, up from $5.6b last year. More | Follow @FiercePharma

 @EricPFierce: Government-funded vaccine plant in Thailand draws the attention of corruption investigators. Report | Follow @EricPFierce

> U.S. feds launch probe into AstraZeneca plant in U.K. Article

> New Bristol-Myers drug growth cushions plummeting Plavix sales. More

> Analysts skeptical as AstraZeneca sales, earnings sink. Report

Vaccines News

> Possible measles-related death in Wales as outbreak spreads. Item

> Novartis expands cell culture site to bolster biodefense. News

> China's response to H7N9 earns WHO praise. Story

> No link between vaccines and Guillain-Barré in big study. Article

> Panacea Biotec accused of selling expired vaccines. More

Pharma Manufacturing News

> FDA gets Corning to refine agency-designed counterfeit drug scanner. Item

> Eisai building plant in China to manufacture parenteral products. Story

> AstraZeneca hears from prosecutor, not FDA, about cGMPs at U.K. plant. Report

> BD quickly rolling out second drug from new injectables plant. Article

And Finally… Right now the mortality rate for H7N9 is 21%, and with human immunity to the virus still very low, health officials expect to see the death toll rise. Story

 

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

Scorpion is working on precision oncology 2.0, which includes making better drugs for known targets, hit undruggable targets and discover new targets.

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.